UBS Group
NYMX

UBS Group’s Nymox Pharmaceutical Corp NYMX Stock Holding History

UBS Group’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-34,530
Closed -$6.56K – 10355
2023
Q2 		$6.56K Buy
34,530
+34,155
+9,108% +$13.4K ﹤0.01% 7357
2023
Q1 		$128 Hold
375
– – ﹤0.01% 9199
2022
Q4 		$120 Hold
375
– – ﹤0.01% 10380
2022
Q3 		$0 Sell
375
-550
-59% -$219 ﹤0.01% 11368
2022
Q2 		$0 Buy
925
+375
+68% +$345 ﹤0.01% 11362
2022
Q1 		$1K Hold
550
– – ﹤0.01% 10039
2021
Q4 		$1K Sell
550
-2,783
-83% -$4.44K ﹤0.01% 10110
2021
Q3 		$7K Sell
3,333
-1,889
-36% -$3.35K ﹤0.01% 8364
2021
Q2 		$8K Sell
5,222
-13,864
-73% -$25.7K ﹤0.01% 8275
2021
Q1 		$42K Buy
19,086
+7,579
+66% +$20K ﹤0.01% 6734
2020
Q4 		$28K Buy
11,507
+9,898
+615% +$21.9K ﹤0.01% 6705
2020
Q3 		$4K Sell
1,609
-12,120
-88% -$35.3K ﹤0.01% 7463
2020
Q2 		$49K Buy
13,729
+12,597
+1,113% +$39.8K ﹤0.01% 5881
2020
Q1 		$3K Sell
1,132
-1,021
-47% -$2.87K ﹤0.01% 7543
2019
Q4 		$5K Sell
2,153
-972
-31% -$1.92K ﹤0.01% 7609
2019
Q3 		$6K Sell
3,125
-1,944
-38% -$3.4K ﹤0.01% 7441
2019
Q2 		$7K Sell
5,069
-1,828
-27% -$3.2K ﹤0.01% 7269
2019
Q1 		$14K Sell
6,897
-5,050
-42% -$10.7K ﹤0.01% 6609
2018
Q4 		$16K Buy
11,947
+2,107
+21% +$3.86K ﹤0.01% 6963
2018
Q3 		$24K Buy
9,840
+5,717
+139% +$16.9K ﹤0.01% 6707
2018
Q2 		$14K Buy
4,123
+2,986
+263% +$11.5K ﹤0.01% 6955
2018
Q1 		$5K Sell
1,137
-3,098
-73% -$10.7K ﹤0.01% 7257
2017
Q4 		$14K Sell
4,235
-888
-17% -$3.24K ﹤0.01% 6825
2017
Q3 		$19K Sell
5,123
-21,968
-81% -$83.3K ﹤0.01% 6501
2017
Q2 		$119K Buy
27,091
+12,573
+87% +$51.6K ﹤0.01% 5062
2017
Q1 		$53K Buy
14,518
+976
+7% +$3.21K ﹤0.01% 5486
2016
Q4 		$36K Buy
+13,542
New +$42K ﹤0.01% 6096
2016
Q3 		– Sell
-81
Closed – – 8016
2016
Q2 		$0 Buy
81
+4
+5% +$10 ﹤0.01% 8047
2016
Q1 		$0 Buy
+77
New +$182 ﹤0.01% 8347
2015
Q4 		– Sell
-697
Closed -$2K – 8646
2015
Q3 		$2K Sell
697
-568
-45% -$1.32K ﹤0.01% 8118
2015
Q2 		$2K Sell
1,265
-1,510
-54% -$2.11K ﹤0.01% 8231
2015
Q1 		$2K Sell
2,775
-28,175
-91% -$13.3K ﹤0.01% 8471
2014
Q4 		$12K Buy
+30,950
New +$66K ﹤0.01% 8255

Other funds holding NYMX

DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
CAM
Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return
ODIJL
One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

UBS Group's NYMX Position: Q3 2023 in Review

UBS Group sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 34,530 shares — an estimated $6.56K sold.

UBS Group first reported a position in NYMX in Q4 2014 and held it in 33 quarters. The position peaked at $119K in Q2 2017. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

  • UBS Group reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 34,530 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $6.56K.
  • UBS Group first reported a position in Nymox Pharmaceutical Corp in Q4 2014 and held it in 33 quarters.
  • UBS Group's Nymox Pharmaceutical Corp position peaked at $119K in Q2 2017.
  • 5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.